Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

PRME


Fundamental

Company: Prime Medicine Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -1.48
Insider Own: 48.03%
Shs Outstand: 180.31M
Perf Week: -7.56%
Market Cap: 595.69M
Forward P/E: -
EPS next Y: -0.93
Insider Trans: 0.00%
Shs Float: 93.82M
Perf Month: -23.43%
Enterprise Value: 500.54M
PEG: -
EPS next Q: -0.25
Inst Own: 46.46%
Short Float: 28.86%
Perf Quarter: -7.04%
Income: -197.34M
P/S: 99.61
EPS this Y: 19.76%
Inst Trans: 25.18%
Short Ratio: 7.79
Perf Half Y: -9.34%
Sales: 5.98M
P/B: 3.68
EPS next Y Percentage: 30.06%
ROA: -54.98%
Short Interest: 27.08M
Perf YTD: -4.90%
Book/sh: 0.90
P/C: 2.79
EPS next 5Y: 20.13%
ROE: -112.34%
52W High: 6.94 -52.45%
Perf Year: 27.17%
Cash/sh: 1.18
P/FCF: -
EPS past 3/5Y: 4.95% -124.13%
ROIC: -72.49%
52W Low: 1.11 197.30%
Perf 3Y: -84.30%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -19.83%
Volatility W: 6.84%
Volatility M: 8.81%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 83.70
EPS Y/Y TTM: 26.79%
Oper. Margin: -3412.48%
ATR (14): 0.31
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 6.61
Sales Y/Y TTM: 647.12%
Profit Margin: -3301.64%
RSI (14): 39.37
Recom: 1.67
Dividend Gr. 3/5Y: - -
Current Ratio: 6.61
EPS Q/Q: 28.12%
SMA20: -13.62%
Beta: 2.74
Target Price: 6.41
Payout: -
Debt/Eq: 0.73
Sales Q/Q: 486.12%
SMA50: -13.97%
Rel Volume: 0.41
Prev Close: 3.32
Employees: 214
LT Debt/Eq: 0.68
Earnings: Nov 07 BMO
SMA200: -9.16%
Avg Volume: 3.48M
Price: 3.30
IPO: Oct 20, 2022
Option/Short: Yes / Yes
EPS/Sales Surpr.: -26.53% -52.54%
Trades:
Volume: 1,436,091
Change: -0.60%

Technical:


Latest News:

Citigroup Upgrades Prime Medicine (PRME) - Nasdaq very bullish
PRME

Summary: Citigroup upgraded their outlook for Prime Medicine from Neutral to Buy with an analyst price forecast suggesting 114.11% upside. Various funds and institutions have reported positions in Prime Medicine, totaling 70,064K shares, with a bullish outlook indicated by the put/call ratio of 0.12.

Full article
2024-05-17T22:16:55Z